Please assess the completion status of the following clinical trial:

Trial Title: Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Relapsed or refractory acute lymphoblastic leukemia (ALL) with \> 10% bone marrow or peripheral blood blasts per WHO-criteria. Refractory define as failure to achieve CR after prior therapy.~* Previously untreated patients \> 60, if not candidates for standard induction~* Age ≥ 18~* Not a candidate for curative treatment regimens~* Unwilling or unable to receive conventional chemotherapy~* ECOG performance status ≤ 2~* Life expectancy \> 2 months~* Registered to in RevAssist restricted distribution program, and willing and able to comply with the program requirement~* Females of childbearing potential (FCBP):~  * Must have a negative serum or urine pregnancy test (sensitivity of at least 50 mIU/mL) 10 to 14 days prior to study enrollment and within 24 hours prior to prescribing lenalidomide~ * Must either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control~ * Agree to ongoing pregnancy testing~* Men must agree to use a latex condom during sexual contact with a FCBP~* Able to adhere to the study visit schedule and other protocol requirements~* Willing and able to understand and voluntarily sign a written informed consent~Exclusion Criteria:~* Prior therapy with lenalidomide~* History of intolerance to thalidomide including development of erythema nodosum while taking thalidomide or similar drugs~* Advanced malignant hepatic tumors.~* Concomitant treatment with other anti-neoplastic agents (exception hydroxyurea)~* Anti-neoplastic treatment less than 4 weeks prior to enrollment (exception hydroxyurea)~* Use of any other experimental drug or therapy within 14 days of baseline~* Inability to swallow or absorb drug~* Active opportunistic infection or treatment for opportunistic infection within 4 weeks of first dose of study drug~* New York Heart Association Class III or IV heart failure~* Unstable angina pectoris~* Cardiac arrhythmias with rapid ventricular response (heart rate \> 100 beats/minute)~* Uncontrolled psychiatric illness that would limit compliance with requirements~* Known HIV infection~* Known active hepatitis B virus (HBV) (exception seropositivity due to HBV vaccine not considered active HBV)~* Known hepatitis C virus (HCV) infection~* Pregnant~* Lactating females must agree not to breastfeed while taking lenalidomide~* Other medical or psychiatric illness or organ dysfunction or laboratory abnormality which in the opinion of the investigator would compromise the patient's safety or interfere with data interpretation~* Creatinine ≥ 1.5 mg/dL~* Creatinine clearance ≤ 60 mL/min.~* Total bilirubin \> 1.5 x institutional upper limit of normal (ULN) (exception documented Gilbert's syndrome)~* AST and ALT \> 3 x institutional ULN

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lenalidomide 50 mg/day x 28 days (Type: EXPERIMENTAL): Lenalidomide 50 mg daily for 28 consecutive days every 42 days (+/-7 days). Treatment to continue until evidence of disease progression or development of unexpected toxicities not reversed by dose reductions and/or interruptions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues